Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Riedl, JM; Posch, F; Moik, F; Bezan, A; Szkandera, J; Smolle, MA; Kasparek, AK; Pichler, M; Stöger, H; Stotz, M; Gerger, A.
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting.
Oncotarget. 2017; 8(56):96048-96061 Doi: 10.18632/oncotarget.21647 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Riedl Jakob

Stotz Michael

Co-Autor*innen der Med Uni Graz

Gerger Armin

Kasparek Anne-Katrin

Moik Florian

Pichler Martin

Posch Florian

Smolle Maria Anna

Stöger Herbert

Szkandera Joanna

Terbuch Angelika

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Introduction: Inflammatory biomarkers are useful prognostic tools in cancer patients. However, the prognostic and predictive value of inflammatory biomarkers beyond the 1^st-line setting in metastatic colorectal cancer (mCRC) is unclear. Results: In multivariate analysis 1 standard deviation increase in neutrophil-lymphocyte-ratio (NLR) was associated with an 8.5% absolute lower objective-response-rate (ORR) in 1^st-line (p<0.0001), 3% lower ORR in 2^nd-line (p< 0.0001), and 3% lower ORR in 3^rd-line (p=0.24), respectively. Regarding progression free survival (PFS), an increase in the NLR was significantly associated with rising hazard-ratios (HR) over all treatment lines (HR=1.30, p= 0.021 1^st-line); (HR=1.37, p<0.0001 2^nd-line); (HR=1.44, p=0.042 3^rd-line). The platelet-lymphocyte-ratio (PLR) was associated with 6-month PFS over all three treatment lines. Higher C-reactive-protein (CRP) predicted for worse PFS in the first two chemotherapy lines and in best supportive care (BSC). (HR=1.49 (p<0.0001 1^st-line); HR=1.25 (p=0.007 2^nd-line); HR=1.09 (95%CI 0.81-1.48, p=0.552 3^rd-line and HR=1.43 (p= 0.002 in BSC)). Methods: Two-hundred-fifty-eight patients with mCRC undergoing palliative chemo(immuno-)therapy were retrospectively included. Primary endpoints were 6-month PFS and ORR during 1st-line, 2nd-line, and 3rd-line treatment, and 6-month overall survival during BSC. Conclusion: This study shows that inflammatory biomarkers are useful predictors of disease outcome and treatment response over several treatment lines in mCRC patients.

Find related publications in this database (Keywords)

biomarker

inflammation

metastatic

colorectal cancer

palliative chemotherapy

© Med Uni Graz • Impressum